Evidence map›Paper›PMID 31475108›Full record

ArticleFrontiers in oncology2019

Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck.

Sati Akbaba, Andreas Mock, Juliane Hoerner-Rieber, Thomas Held, Sonja Katayama, Tobias Forster, Christian Freudlsperger, Stefan Rieken, Klaus Herfarth, Peter Plinkert and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sati AkbabaDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Andreas MockDepartment of Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Juliane Hoerner-RieberDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Thomas HeldDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Sonja KatayamaDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Tobias ForsterDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Christian FreudlspergerDepartment of Oral and Maxillofacial Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Stefan RiekenDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Klaus HerfarthDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Peter PlinkertDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Juergen DebusDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Sebastian AdebergDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
National Center for Tumor Diseases · DEUniversity Hospital Heidelberg · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

carbon ion radiotherapyintestinal-type adenocarcinomalocal controlsalivary duct adenocarcinomasalivary gland adenocarcinomaside effectstomotherapy

Identifiers

PMID31475108
PMCPMC6705231
OpenAlexW2966687658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.